Oncimmune Holdings PLC - Leeds, England-based autoantibody profiling research services to pharmaceutical and biotechnology industry to enable delivery of precision medicine - Raises £2.2 million from placing of 12.0 million new shares and subscription for 2.3 million more, all at 15 pence. The results of the placing, run as an accelerated bookbuild by brokers Cavendish and Zeus, is in line with plans set out early Friday. Oncimmune also plans a retail share offer of up to 2.0 million shares to raise an additional £300,000.

In addition to the share offers, Oncimmune recapitalised two-thirds of its debt, with €4.0 million in existing debt converted into equity at the same price of 15p per share. That will leave €4.0 million in principal debt outstanding for Oncimmune.

Oncimmune had said the fresh equity will support recent contract wins and prepare for its ‘next stage of growth’.

Current stock price: 15.80p, up 2.9% on Monday in London

12-month change: down 7.3%

Copyright 2024 Alliance News Ltd. All Rights Reserved.